A share price of Neurocrine Biosciences, Inc [NBIX] is currently trading at $122.21, up 1.61%. An important factor to consider is whether the stock is rising or falling in short-term value. The NBIX shares have gain 5.28% over the last week, with a monthly amount glided 9.23%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler upgraded its rating to Overweight on August 29, 2024, and elevated its price target to $159. On April 24, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $170 on the stock. Deutsche Bank initiated its recommendation with a Buy and recommended $136 as its price target on December 12, 2023. In a note dated August 21, 2023, Mizuho reiterated an Neutral rating on this stock and boosted its target price from $112 to $113.
Neurocrine Biosciences, Inc experienced fluctuations in its stock price throughout the past year between $103.63 and $157.98. Currently, Wall Street analysts expect the stock to reach $147.7 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $122.21 at the most recent close of the market. An investor can expect a potential return of 20.86% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
Trailing Twelve Months sales for Neurocrine Biosciences, Inc [NASDAQ:NBIX] were 2.24B which represents 24.72% growth. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.11, Equity is 0.16 and Total Capital is 0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 120.82 points at the first support level, and at 119.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 123.30, and for the 2nd resistance point, it is at 124.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Neurocrine Biosciences, Inc [NASDAQ:NBIX] is 4.37. On the other hand, the Quick Ratio is 4.26, and the Cash Ratio is 0.81. Considering the valuation of this stock, the price to sales ratio is 5.61, the price to book ratio is 4.55 and price to earnings (TTM) ratio is 32.74.
Transactions by insiders
Recent insider trading involved Boyer David W., Chief Corp. Affairs Officer, that happened on Sep 13 ’24 when 3461.0 shares were sold. Officer, DAVID WARREN BOYER completed a deal on Sep 13 ’24 to buy 4756.0 shares. Meanwhile, Director RASTETTER WILLIAM H sold 14250.0 shares on Aug 15 ’24.
